The mTOR inhibitor (mammalian target-of-rapamycin inhibitor) Everolimus (EVL) is an antiproliferative immunosuppressive drug without significant nephrotoxicity, but with side effects such as mouth ulcerations, dyslipidemia and impaired wound healing [15]. Here, MTOR is linked to metabolic syndrome.